NVAX – Novavax, Inc.

Float Short %

34.97

Margin Of Safety %

Put/Call OI Ratio

0.63

EPS Next Q Diff

1.25

EPS Last/This Y

3.38

EPS This/Next Y

-2.01

Price

6.57

Target Price

12.67

Analyst Recom

2.5

Performance Q

-18.69

Relative Volume

0.69

Beta

2.37

Ticker: NVAX

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-13	NVAX	7.06	0.68	0.30	310913
2025-11-14	NVAX	6.97	0.67	0.11	313727
2025-11-17	NVAX	6.8	0.68	0.25	306767
2025-11-18	NVAX	6.57	0.68	0.28	310120
2025-11-19	NVAX	6.34	0.67	0.22	311635
2025-11-20	NVAX	6.22	0.64	0.09	324927
2025-11-21	NVAX	6.47	0.65	0.31	327670
2025-11-24	NVAX	6.63	0.65	0.06	299032
2025-11-25	NVAX	6.7	0.63	0.11	304051
2025-11-26	NVAX	6.95	0.63	0.08	305311
2025-12-01	NVAX	6.7	0.64	0.07	301793
2025-12-02	NVAX	6.59	0.63	0.14	303838
2025-12-03	NVAX	6.84	0.63	0.05	305127
2025-12-04	NVAX	6.86	0.63	0.22	306375
2025-12-05	NVAX	6.91	0.63	0.07	307731
2025-12-08	NVAX	6.78	0.65	0.13	299991
2025-12-09	NVAX	6.66	0.64	0.16	303937
2025-12-10	NVAX	6.74	0.64	0.14	305798
2025-12-11	NVAX	6.69	0.63	0.18	306658
2025-12-12	NVAX	6.57	0.63	0.07	306996
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-13	NVAX	7.07	-48.8	-	2.16
2025-11-14	NVAX	6.98	-33.7	-	2.28
2025-11-17	NVAX	6.80	-15.2	-	2.28
2025-11-18	NVAX	6.57	-15.2	-	2.28
2025-11-19	NVAX	6.34	-15.2	-	2.28
2025-11-20	NVAX	6.22	-15.2	-	2.15
2025-11-21	NVAX	6.47	-5.6	-	2.15
2025-11-24	NVAX	6.63	-5.6	-	2.15
2025-11-25	NVAX	6.69	-5.6	-	2.15
2025-11-26	NVAX	6.95	-5.6	-	2.15
2025-12-01	NVAX	6.70	-5.6	-	2.15
2025-12-02	NVAX	6.60	-5.6	-	2.15
2025-12-03	NVAX	6.84	-5.6	-	2.15
2025-12-04	NVAX	6.87	-5.6	-	2.15
2025-12-05	NVAX	6.91	-5.6	-	2.15
2025-12-08	NVAX	6.78	-5.6	-	2.15
2025-12-09	NVAX	6.66	-5.6	-	2.15
2025-12-10	NVAX	6.74	-5.6	-	2.15
2025-12-11	NVAX	6.69	-5.6	-	2.15
2025-12-12	NVAX	6.57	-5.6	-	2.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-13	NVAX	0.00	1.26	32.62
2025-11-14	NVAX	0.00	1.26	32.58
2025-11-17	NVAX	0.00	2.59	32.58
2025-11-18	NVAX	0.00	2.59	32.58
2025-11-19	NVAX	0.00	2.59	32.58
2025-11-20	NVAX	0.00	2.59	32.58
2025-11-21	NVAX	0.00	2.59	32.58
2025-11-24	NVAX	0.00	0.71	32.58
2025-11-25	NVAX	0.00	0.71	32.58
2025-11-26	NVAX	0.00	0.71	34.17
2025-12-01	NVAX	0.00	0.66	34.17
2025-12-02	NVAX	0.00	0.66	34.17
2025-12-03	NVAX	0.00	0.66	34.17
2025-12-04	NVAX	0.00	0.66	34.17
2025-12-05	NVAX	0.00	0.66	34.17
2025-12-08	NVAX	0.00	0.63	34.17
2025-12-09	NVAX	0.00	0.63	34.17
2025-12-10	NVAX	0.00	0.63	34.97
2025-12-11	NVAX	0.00	0.63	34.97
2025-12-12	NVAX	0.00	0.63	34.97
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="NVAX" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-1.25

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

0.63

Beta

2.37

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

114

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-98.8

Target Price

12.67

P/E

3.71

Forward P/E

270.04

PEG

3.77

P/S

P/B

P/Free Cash Flow

EPS

1.77

Average EPS Est. Cur. Y

2.15

EPS Next Y. (Est.)

0.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.1

Relative Volume

0.69

Return on Equity vs Sector %

-245

Return on Equity vs Industry %

-230

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.43

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”NVAX” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NVAX” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NVAX” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NVAX” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NVAX” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NVAX” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NVAX” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Novavax, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 952

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

stock quote shares NVAX – Novavax, Inc. Stock Price stock today

news today NVAX – Novavax, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NVAX – Novavax, Inc. yahoo finance google finance

stock history NVAX – Novavax, Inc. invest stock market

stock prices NVAX premarket after hours

ticker NVAX fair value insiders trading

NVAX – Novavax, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVAX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y